SEC Form N-CSRS filed by BlackRock Technology and Private Equity Term Trust
$BTX
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/29/2021 | $9.00 | Overweight | Cantor Fitzgerald |
| 10/6/2021 | $20.00 | Buy | Maxim Group |
N-CSRS - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
N-PX - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
SCHEDULE 13D/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00
Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00
4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)
3 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
The Board of Trustees (the "Board") of BlackRock Health Sciences Term Trust (BMEZ), BlackRock Science and Technology Term Trust (BSTZ), and BlackRock Technology and Private Equity Term Trust (BTX) (the "Funds") approved updates to each Fund's managed distribution plan that will take effect with the October 2025 distribution. The Funds will change from a floating rate distribution to a level rate distribution at the stated monthly rates provided below. These changes seek to enhance distribution stability while maintaining a competitive distribution rate and offering the potential to grow each Fund's net asset value. Additionally, these changes will help to manage the proportion of public and
The BlackRock Sector Equity Closed End Funds (CEFs) listed below (the "Funds") announced today that each Fund's Board of Trustees (the "Board") has approved the following updates to the Funds' respective investment objectives and principal investment strategies. Effective 11/10/2025, the Funds' investment objectives will be changed as indicated below. Investment objective changes BlackRock Sector CEFs Ticker Current Investment Objective Proposed Investment Objective BlackRock Resources and Commodities Strategy Trust BCX The Trust's primary investment objective is to seek high current income and current gains, with a secondary objective
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 9/2/2025 Ex-Date- 9/15/2025 Record- 9/15/2025 Payable- 10/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Q
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 9/2/2025 Ex-Date- 9/15/2025 Record- 9/15/2025 Payable- 10/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Q
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 8/1/2025 Ex-Date- 8/15/2025 Record- 8/15/2025 Payable- 9/2/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)